Document is current
Any future updates will be listed below
-
Authors
Bouza, Emilio
Cornely, Oliver A.
Ramos-Martinez, Antonio
Plesniak, Robert
Ellison, Misoo C.
Hanson, Mary E.
Dorr, Mary Beth
-
Funding
Funding for this research was provided by:
Merck
- License Information
-
More Information
Article History
Received: 29 March 2020
Accepted: 24 May 2020
First Online: 6 June 2020
Compliance with ethical standards
:
: EB has participated in clinical trials and advisory boards sponsored by MSD, Pfizer, and Astellas. ARM has participated in clinical trials sponsored by MSD. RP has participated in clinical trials sponsored by MSD. OAC has received research grants from, is an advisor to, or received lecture honoraria from Actelion, Allecra Therapeutics, Amplyx, Arsanis, Astellas, AstraZeneca, Basilea, Bayer, Cidara, Da Volterra, F2G, Gilead, GSK, IQVIA, Janssen, Leeds University, Matinas, The Medicines Company, Medpace, Melinta, Menarini, MSD, Miltenyi, Paratek, Pfizer, PSI, Rempex, Roche, Sanofi Pasteur, Scynexis, Seres, Summit, Tetraphase, and Vical. MCE, MEH, and MBD are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and may own stock and/or restricted stock units in Merck & Co., Inc., Kenilworth, NJ, USA.
: Both MODIFY I and II were conducted in accordance with the Good Clinical Practice guidelines and the Declaration of Helsinki. The protocols and amendments were approved by the institutional review board or independent ethics committee at each study site. Written informed consent was provided by all participants before the trial began.
